New Purchase and Sale Agreements, Regulatory Statements, Joint Venture Formation, and Legal Updates - Analyst Notes on Shell, HSBC, BP, GSK and Vodafone

LONDON, June 3, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Earnings Review released its analysts' notes regarding Royal Dutch Shell Plc (LON: RDSA), HSBC Holdings plc (LON: HSBA), BP Plc (LON: BP), GlaxoSmithKline plc (LON: GSK) and Vodafone Group plc (LON: VOD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://earnings-review.com/3263-100free.

--
Royal Dutch Shell Plc Analyst Notes
On May 29, 2014, Shell Eastern Trading (Pte) Ltd, a Singapore-based subsidiary of Royal Dutch Shell Plc (Shell) announced that it has signed a sales and purchase agreement with Japan's Chubu Electric Power Co., Inc. (Chubu Electric) to supply up to 12 cargoes of LNG every year for the next two decades starting October 2014. Shell informed that this is the first long-term LNG deal directly between Shell and Chubu Electric. Commenting on the agreement, Maarten Wetselaar, Executive Vice President, Shell Integrated Gas, said, "It further underlines our strength in the LNG market as we mark our 50th year in LNG. As one of the world's largest LNG producers and marketers, with a strong, diverse portfolio, we are well positioned to respond flexibly to short term changes in demand and help ensure security of supply for the companies and countries we work with." The full analyst notes on Shell are available to download free of charge at:

http://earnings-review.com/3263-RDSA-03Jun2014.pdf

--
HSBC Holdings plc Analyst Notes
On May 19, 2014, HSBC Bank Malta plc., (HSBC Malta) a subsidiary of HSBC Holdings plc (HSBC) issued a statement under the listing Rules 5.86 and 5.88 of the Malta Financial Services Authority (period: January 1, 2014 to May 19, 2014). HSBC Bank Malta stated that during the above stated period, the Bank posted results that fell short, when compared to last year's performance, primarily due to difficult market conditions. Margin compression, slow loan growth and a reduced contribution from the life insurance business, in 2014, compared to the same period in 2013, which included a significant one-off gain, also adversely impacted this year's results. In addition, operating expenses too increased due to compliance investments and increased regulatory fees. However, the Company noted that underlying expenses have been well controlled and significant work continues around streamlining the business for greater efficiencies. The full analyst notes on HSBC are available to download free of charge at:

http://earnings-review.com/3263-HSBA-03Jun2014.pdf

--
BP Plc Analyst Notes
On May 24, 2014, BP Exploration Operating Company Ltd. (BP Exploration) - a subsidiary of BP Plc (BP) and Russia's Rosneft signed a Heads of Agreement on Domanik formations within the framework of the St. Petersburg International Economic Forum. BP informed that both the Companies will form a joint venture company in which BP will own 49% and Rosneft will hold the remaining 51%. According to the terms of the agreement, both companies will implement a joint pilot project related to the Domanik formations and, in the event of success, the possible development of unconventional Domanik resources in the Volga-Urals region. In addition, BP will compensate a part of historical cost to Rosneft for exploration of the Domanik formations and will provide carry financing of up to $300 million for the pilot program, which will be conducted in two phases at license blocks in the Orenburg Region. The full analyst notes on BP are available to download free of charge at:

http://earnings-review.com/3263-BP-03Jun2014.pdf

--
GlaxoSmithKline plc Analyst Notes
On May 27, 2014, GlaxoSmithKline plc (GSK) issued a press release informing that the UK's Serious Fraud Office (SFO) has initiated a formal criminal investigation into the Group's commercial practices. GSK reported that it is committed to follow the highest ethical standards, while operating its businesses, and that the Company will continue to cooperate fully with the SFO. The full analyst notes on GSK are available to download free of charge at:

http://earnings-review.com/3263-GSK-03Jun2014.pdf

--
Vodafone Group plc Analyst Notes
On May 23, 2014, a new report commissioned by Vodafone from Analysys Mason, stated that European consumers may suffer from a decline in competition in the mobile market over the next couple of years, unless mobile operators can access fibre backhaul, owned by incumbent operators, at reasonable prices. Currently, the market for broadband access does not consider the need of mobile operators for access to fibre links that carry mobile traffic from base stations back to the core network. This need is accelerating as 4G/LTE traffic grows in line with consumer demand for high-speed services and places strain on existing backhaul technologies. Vodafone appealed to the European Commission, BEREC and national regulatory authorities to explicitly consider the future impact of lack of access to regulated wholesale fibre on competition in the mobile market in the current review of relevant markets, which happens once in seven years. The full analyst notes on Vodafone are available to download free of charge at:

http://earnings-review.com/3263-VOD-03Jun2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] earnings-review.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] earnings-review.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] earnings-review.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Earnings Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Earnings Review in this article or report according to the procedures outlined by Earnings Review. Earnings Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Earnings Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Earnings Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Earnings Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Earnings Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Earnings Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.